An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Conclude your understanding of lymphoma with an in-depth look at its signs and symptoms, from common indicators to subtle clues.

Speaker : Dr Suvir Singh

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2

Explore the impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, drawing insights from the pivotal PALOMA-2 study presented by Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

Discover the comprehensive impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, with key insights from the PALOMA-2 study presented by Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

Explore the multifaceted advantages of CDK4/6 inhibitors in HR+/HER2- breast cancer, based on the PALOMA-2 study, in this insightful session with Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

A detailed discussion on the benefits of using CDK4/6 inhibitors in HR+/ HER2-aBC in clinical trials.

Speakers : Dr. Bhavna Parikh

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

The webinar gives insights into the role of pazopanib in managing renal cell carcinoma.

Speakers : Dr. Yogesh Kumar ,Dr. Pankaj Goyal ,Dr. Jatin Sarin ,Dr. Ankur Punia


Recommended News For You

Report: Breast cancer mortality continues three decade decline, but steeper increases in incidence for some women

Words matter to people living with cancer. Here's how verbal microaggressions affect their mental state

Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy

In a clinical trial, "3D mammography" nearly reduces the incidence of breast cancer between two screening exams.

The Higher the Disability Burden From Disease, the Higher the Suicide Risk

AI tool accurately detects tumor location on breast MRI

Cancer detection recovered following pandemic disruptions

Recommended Articles For You

Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders 

The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease  

Unveiling the Mystery Behind Lymphovascular Invasion 

Molecular & Genetic Oncology: Emerging Frontiers in 2025 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

2.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

3.

Survival improved with lobectomy, segmentectomy in early non-small cell lung cancer

4.

Prostate cancer 'is not a death knell': Early detection and personalized care improve outcomes, study shows

5.

Two medications might work better for breast cancers that are resistant to one.

1.

A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology

2.

Understanding Epoetin and Its Role in Treating Chronic Kidney Disease 

3.

Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes

4.

Management of Relapsed Synovial Sarcoma: Current Treatment Strategies and Emerging Therapies

5.

Exploring the Mysteries of Myxoma: A New Frontier in Medical Research

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

2.

Thromboprophylaxis In Medical Settings

3.

Oropharyngeal Cancer in Relation to HPV Status

4.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II

5.

Navigating the Complexities of Ph Negative ALL - Part XV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot